The incidence of brain metastases in patients with renal cell carcinoma (RCC) is hypothesized to have increased in the last two decades. Our objective was to provide an overview of recent incidence trends in patients with primary renal cell carcinoma (RCC) and brain metastases at diagnosis using a nationally representative cancer cohort originating from the United States. Secondary objectives include developing a tool for prediction of brain metastases at diagnosis and to assess their oncological outcomes, and externally validating it in second database.
INTRODUCTION AND OBJECTIVES:
The incidence of brain metastases in patients with renal cell carcinoma (RCC) is hypothesized to have increased in the last two decades. Our objective was to provide an overview of recent incidence trends in patients with primary renal cell carcinoma (RCC) and brain metastases at diagnosis using a nationally representative cancer cohort originating from the United States. Secondary objectives include developing a tool for prediction of brain metastases at diagnosis and to assess their oncological outcomes, and externally validating it in second database.
METHODS: All patients with a primary diagnostic confirmation of RCC within the Surveillance, Epidemiology, and End Results (SEER, 2010 (SEER, -2013 database and the National Cancer Database (NCDB, 2010 (NCDB, -2012 were abstracted. The incidence proportions (%IP) and 95% confidence intervals (CI) of brain metastases were calculated overall and according to patient, sociodemographic, and disease characteristics. A 1000-bootstrap corrected multivariable logistic regression models was developed for prediction of brain metastases at diagnosis using the SEER cohort (development). Backward variable selection was conducted to identify the most parsimonious model. Model performance was evaluated via measures of predictive accuracy in the NCDB cohort (validation).
RESULTS: The overall %IP of brain metastases at RCC diagnosis was 1.51% (95% CI: 1.39-1.64) in the SEER and 1.37% (95% CI: 1.29-1.45%) in the NCDB. The odds of harbouring brain metastases at RCC diagnosis varied significantly according to sociodemographic and clinical characteristics. Following backward variable selection within the SEER database, only histology, tumor size, and cN stages were retained in the final model. Predictive accuracy was adequate in the external validation cohort (C-statistic: 0.778). Median time to any death was 6.37 months in patients with brain metastases. After adjusting for confounders, patients with brain metastases were more likely to succumb to any death than those without brain metastases at diagnosis (hazard ratio: 1.87, 95% CI: 1.71-2.05, P<0.001).
CONCLUSIONS: The incidence of brain metastases in patients with RCC is increasing. The oncological outcomes of such patients remain poor and their treatment management variable. A clinical risk model including cN-stage, histology and tumor size can predict the presence of brain metastases at diagnosis and may justify baseline imaging in asymptomatic but high-risk patients.
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MP22-19 ALLOGENEIC BLOOD TRANSFUSION IS ASSOCIATED WITH INCREASED MORTALITY AND INFECTIOUS COMPLICATIONS AFTER NEPHROURETERECTOMY
Michael Lam*, Nicholas Chakiriyan, Ann Martinez-Acevedo, Christopher Amling, Jen-Jane Liu, Portland, OR INTRODUCTION AND OBJECTIVES: Allogeneic blood transfusions (ABT) may have an immunosuppressive effect on patients via transfusion-related immunomodulation, particularly in patients undergoing cancer surgery. Prior studies have demonstrated strong causality data among patients with colorectal, lung, and hepatobiliary cancers, however the existing data remains mixed in renal malignancies. We examined whether ABT's increase the risk of mortality and complications (including perioperative infections) after open and minimally invasive nephroureterectomy.
METHODS: We used the National Surgical Quality Improvement Program (2010 Program ( to 2013 to study the use of ABT as well as identify the rate of post-operative mortality and complications. Subgroup analysis of infectious complications assessed surgical site infection, pneumonia, abscess, urinary tract infection, and sepsis. We examined the association between ABT and mortality, any perioperative complications, and infectious complications after controlling for potential confounders (ASA status, age, race, diabetes, and operative time).
RESULTS: We identified 1,691 nephroureterectomies (534 open, 1157 minimally invasive) performed during the study period. The rate of ABT was 23.6% for open and 8.64% for minimally invasive (13.4% overall). Patients who received an ABT had an increased risk of mortality (5.39% vs 1.09%, p < 0.001), any perioperative complication (30.53% vs 9.97%, p < 0.001), and infectious complications (13.72% vs 4.64%, p < 0.001). After adjusting for potential confounders, ABT remained an independent predictor for all complications, infectious complications, and mortality (p < 0.001).
CONCLUSIONS: This analysis supports the concept that ABTs are independently associated with an increased risk of perioperative complications, particularly infectious ones. Urologists should use evidence-based "restrictive" transfusion thresholds to minimize perioperative morbidity and mortality ABTs when performing nephroureterectomy. . 197, No. 4S, Supplement, Friday, May 12, 2017 
